Results 121 to 130 of about 26,436 (212)

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Katja Taxis, Frank G. A. Jansman   +5 more
wiley   +1 more source

Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer

International Journal of Cancer, Volume 159, Issue 8, Page 1974-1989, 15 October 2026.
Although lenvatinib is the current first‐line therapy for radioiodine‐refractory differentiated thyroid carcinoma, its use is limited by severe side effects and reduced sensitivity. Here, the authors assessed the potential of sensitizing differentiated thyroid carcinoma tumor cells with limited lenvatinib responsiveness through the administration of ...
Celina Ablinger, Petra Huber‐Cantonati, Daniela D. Weber, Sarah Pichler, Georg Schischkow, Marta Garcia‐Miralles, Christian Pirich, Gundula Rendl, Teresa Kiener, Thomas Felder, Martin Geroldinger, Robert Terkola, Barbara Kofler, Johanna Pachmayr   +13 more
wiley   +1 more source

Tumor peripheral stiffness modulates lenvatinib resistance in HCC preclinical models by regulating FIS1-dependent mitophagy

JHEP Reports
Background & Aims: Hepatocellular carcinoma (HCC) displays heterogeneous responses to lenvatinib, with tumor microenvironment (TME) stiffness emerging as a key resistance modulator.
Kunjin Wu, Jing Li, Yunong Fu, Kaibo Yang, Ting Lin, Yaohui Wang, Ming Wang, Yunxiang Long, Fengping Zhang, Bo Cheng, Yuan Li, Cong Wang, Feng Xu, Chang Liu, Kai Qu   +14 more
doaj   +1 more source

Lenvatinib mesylate to treat hepatocellular carcinoma

, 2019
Hepatocellular carcinoma (HCC) is a worldwide healthcare problem, with a rising incidence. In its advanced stage, the prognosis of untreated HCC is very poor.
Tovoli F., Piscaglia F., Ielasi L.
core   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, Volume 13, Issue 58, 19 October 2026.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Nanoprobe‐Enabled Precision Imaging and Panoramic Boundary Delineation in Retinoblastoma

Cancer Innovation, Volume 5, Issue 5, October 2026.
This review highlights that nanoprobe‐enabled multimodal imaging, combined with targeted probe design and AI‐assisted analysis, significantly enhances the precise visualization and boundary delineation of retinoblastoma. It further outlines key challenges and directions for translating high‐performance imaging nanoprobes into clinical practice.
Xuefei He, Precious Amarachi Ikwuagwu, Wenjing Pang, Aomen Chen, Lingchao Xiang, Feng Chen, Chen Xu, Aiguo Wu   +7 more
wiley   +1 more source

Lenvatinib Versus Sorafenib in First-Line Treatment of Older Patients With Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial

Liver Cancer
Background: In the open-label, phase 3 REFLECT trial, lenvatinib had noninferior overall survival (OS) to sorafenib, as well as improved progression-free survival (PFS) and objective response rate (ORR) in patients with unresectable ...
Masatoshi Kudo, Arndt Vogel, Thomas R. Jeffry Evans, Yuk Ting Ma, Bruno Daniele, Ari David Baron, Amit Mahipal, Shukui Qin, Jean Frederic Blanc, Carlos Lopez Lopez, Ann-Lii Cheng, Su Pin Choo, Fabio Piscaglia, Kalgi Mody, Min Ren, Stephen Lam Chan   +15 more
doaj   +1 more source

Progression‐free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta‐analysis

Cancer, Volume 132, Issue 19, 1 October 2026.
ABSTRACT The objective of this systematic review and meta‐analysis was to evaluate the validity of progression‐free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma.
Russell Leong, David Chen, Laith Almasri, Nicholas Lum, Karren Xiao, Maryam Soleimani, Christian K. Kollmannsberger, Srinivas Raman   +7 more
wiley   +1 more source

Periprocedural Wound Complication Risks in Cancer Pain Patients Following Targeted Cancer Therapy: A Retrospective Analysis

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background In light of the increasing use of advanced operative procedures for cancer pain, it is crucial for pain physicians to understand the unique potential risks associated with multimodal cancer treatments. Aims We aimed to characterize the periprocedural wound healing risk associated with newer targeted cancer therapies in cancer pain ...
Soun Sheen, Vishal Bansal, Xiaowen Sun, Jian Wang, Saba Javed   +4 more
wiley   +1 more source

SERPINE2-mediated activation of JAK2/STAT3 facilitates NRF2 nuclear translocation and GCLC transcription to confer ferroptosis resistance and lenvatinib resistance in hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research
Background Acquired resistance remains a major obstacle in molecular-targeted therapy for advanced hepatocellular carcinoma (HCC). This study aimed to elucidate the role and underlying mechanisms of SERPINE2 in mediating lenvatinib resistance by ...
Kan Liu, Shenglan Huang, Yongkang Xu, Ye Mao, Ning Chen, Yixin Yuan, Qinwen Xiao, Shumin Fu, Jianbing Wu   +8 more
doaj   +1 more source